Radiation Oncology
Review: Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer
30 Apr, 2021 | 08:31h | UTC
M-A: Chemotherapy and radiotherapy in locally advanced head and neck cancer
15 Apr, 2021 | 06:29h | UTC
Commentary on Twitter
What is the best treatment in locally advanced HN Cancer?
Our latest individual patient data network meta-analysis available here for free @TheLancetOncol: https://t.co/UuFvjpKO6I
Many limitations but by far the largest work on the topic (115 RCT, 29000 pts).
#radonc #hncsm pic.twitter.com/eNYHbxsB4Q
— Pierre Blanchard, MD (@PBlanchardMD) April 14, 2021
RCT: No benefit from palliative radiotherapy after esophageal cancer stenting
18 Mar, 2021 | 08:52h | UTC
Cohort study: Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer
14 Mar, 2021 | 20:09h | UTCAssociation of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer – JAMA Oncology (free for a limited period)
Commentary on Twitter
Ablative RT to 98Gy biologically effective dose following multiagent induction therapy for locally advanced pancreatic cancer (LAPC) was safe & resulted in durable locoregional tumor control & favorable survival https://t.co/pLf52Tt6j0 #GICSM
— JAMA Oncology (@JAMAOnc) March 12, 2021
New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer
7 Mar, 2021 | 19:28h | UTCNews Release: New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer – World Health Organization
Technical Document: Technical specifications of radiotherapy equipment for cancer treatment
🆕 guidance on the procurement of radiotherapy equipment released today in collaboration with @iaeaorg, aims to improve access to this life-saving #cancer treatment option that is still lacking in many parts of the world 🌎🌍🌏
👉 https://t.co/fnR0q3DDMq pic.twitter.com/21SHSaQGy7
— World Health Organization (WHO) (@WHO) March 5, 2021
M-A: Local salvage therapies after radiotherapy for prostate cancer
3 Mar, 2021 | 08:06h | UTCA Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) – European Urology (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Pleased to share the results of our "MASTER" systematic review and meta-analysis of local salvage therapies for radioreccurent PCa @EUPlatinum https://t.co/23hy1UtNm5
— Amar Kishan (@AmarUKishan) December 11, 2020
RCT: Endoscopic surgery improves survival compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma
28 Feb, 2021 | 20:45h | UTC
Guidelines in the management of CNS tumors
23 Feb, 2021 | 01:09h | UTCGuidelines in the management of CNS tumors – Journal of Neuro-Oncology
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update
21 Feb, 2021 | 21:47h | UTC
RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer
15 Feb, 2021 | 00:29h | UTC[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today
RCT: Total Body Irradiation vs. Chemotherapy Conditioning in Childhood ALL
9 Feb, 2021 | 00:39h | UTCCommentary: TBI Beats Chemoconditioning for ALL Transplants in Children – Medscape (free registration required)
Commentary on Twitter
Total body irradiation or chemotherapy conditioning in childhood acute lymphoblastic leukemia (ALL) — outcomes suggest there's still a role for TBI https://t.co/ICTC0iEGN8 #leusm #pedonc #pedcsm #JCO pic.twitter.com/xARMBlSeni
— ASCO Publications (@ASCO_pubs) December 26, 2020
Radiation therapy for small-cell lung cancer: ASCO Guideline endorsement of an ASTRO Guideline
29 Jan, 2021 | 01:27h | UTC
ASCO Guideline Update: Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer
28 Jan, 2021 | 01:17h | UTC
Randomized trial: Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer
28 Jan, 2021 | 01:09h | UTC
Commentary on Twitter
🚨 POP-RT P3 RCT in @ASCO_pubs
High-risk prostate cancer & pelvic LN risk ≥20% ➡️
-Prostate only
-Pelvic RTIG-IMRT w/ SIB
-50 Gy/25 fxn to Pelvis
-68 Gy to P+SV⬆️bFFS 95% v 81%
⬆️DFS ~90% v 77%
⬆️DMFS 96% v 89%
✅Low S/Ehttps://t.co/r6YjqWl8Cr#pcsm #radonc #oncoalert pic.twitter.com/d9EL02edcd— Mudit Chowdhary MD (@DrChowdharyMD) January 27, 2021
Randomized trial: Ultra-hypofractionated vs. conventionally fractionated radiotherapy for prostate cancer
19 Jan, 2021 | 01:14h | UTCUltra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
CSCO and ASCO Guideline: Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma
15 Jan, 2021 | 08:14h | UTC
Randomized trial: Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) improve outcomes vs. traditional approach in locally advanced rectal cancer
12 Jan, 2021 | 01:12h | UTCShort-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
New online: phase 3 RAPIDO trial: Short-course #radiotherapy followed by #chemotherapy before total mesorectal excision (TME) vs standard of care in locally advanced #rectalcancer https://t.co/bTgUC6Lo39 #crcsm pic.twitter.com/Iu3HbQ1xjG
— The Lancet Oncology (@TheLancetOncol) December 8, 2020
Meta-analysis: Total neoadjuvant therapy vs. standard therapy in locally advanced rectal cancer
12 Jan, 2021 | 01:10h | UTCCommentaries: Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way AND Total Neoadjuvant Therapy Improves Rectal Cancer Pathologic Response – Physician’s Weekly
Related meta-analysis (just published): Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials – Cancers
Commentary on Twitter
Systematic review & meta-analysis finds total neoadjuvant therapy for locally adv. rectal cancer is associated with a doubling of pathologic complete response vs standard chemoradiation plus by adjuvant chemo. @anup_kasi @KUMedCenter @geriradonc @agrothey https://t.co/oRccCh5bEb
— JAMA Network Open (@JAMANetworkOpen) December 16, 2020
Randomized trial: Among patients with advanced rectal cancer, short-course radiotherapy followed by chemotherapy before total mesorectal excision reduces disease-related treatment failure compared to standard treatment
15 Dec, 2020 | 01:29h | UTC
Commentary on Twitter
New online: phase 3 RAPIDO trial: Short-course #radiotherapy followed by #chemotherapy before total mesorectal excision (TME) vs standard of care in locally advanced #rectalcancer https://t.co/bTgUC6Lo39 #crcsm pic.twitter.com/Iu3HbQ1xjG
— The Lancet Oncology (@TheLancetOncol) December 8, 2020
Short review: How to diagnose and manage radiation therapy cardiotoxicity
6 Dec, 2020 | 23:27h | UTCHow to Diagnose and Manage Radiation Cardiotoxicity – JACC: CardioOncology
Radiation therapy for rectal cancer: Executive summary of an ASTRO clinical practice guideline
28 Oct, 2020 | 08:45h | UTCCommentaries: ASTRO issues clinical guideline on radiation therapy for rectal cancer AND ASTRO Issues Guideline on Radiation Therapy for Rectal Cancer – Physician’s Weekly
Commentary on Twitter
ASTRO issues clinical guideline on #RadiationTherapy for #RectalCancer. Recommendations address #patient selection and treatment techniques for locally advanced disease. This new guideline is published in the #PracticalRO Journal: https://t.co/Q6BDPAOxRI #RadOnc pic.twitter.com/9Zzj5BWA2o
— ASTRO (@ASTRO_org) October 21, 2020
[Abstract Only] Meta-analysis: Adjuvant vs. early salvage radiotherapy for the treatment of localized and locally advanced prostate cancer
29 Sep, 2020 | 10:04h | UTCCommentaries: For Radiotherapy After Radical Prostatectomy, Salvage Therapy Should Be “Standard of Care” – NEJM Journal Watch AND Prostate cancer patients could be spared radiotherapy after surgery as new research suggests there is no benefit and it could be carried out later if the disease comes back – The Daily Mail
Randomized trials: Salvage radiotherapy vs. adjuvant radiotherapy after radical prostatectomy
29 Sep, 2020 | 10:03h | UTCRelated articles: Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial – The Lancet Oncology (free registration required) AND Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial – The Lancet Oncology (free registration required)
Commentaries: For Radiotherapy After Radical Prostatectomy, Salvage Therapy Should Be “Standard of Care” – NEJM Journal Watch AND Prostate cancer patients could be spared radiotherapy after surgery as new research suggests there is no benefit and it could be carried out later if the disease comes back – The Daily Mail
Advanced Prostate Cancer: AUA/ASTRO/SUO Guidelines
24 Sep, 2020 | 09:15h | UTCAdvanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I – The Journal of Urology
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II – The Journal of Urology
[ESMO2020 press release – Not published yet] Randomized trial: No benefit for post-operative radiotherapy in non-small-cell lung cancer
22 Sep, 2020 | 09:23h | UTCCommentary: Phase 3 Trial Results Do Not Support PORT in Resected Stage IIIAN2 NSCLC – Targeted Oncology